Arcus Biosciences, Inc. RCUS

Rank #2296 · NYSE · $2.3B market cap

Audited by Ernst & Young, LLP, no going-concern flag in the latest filing.

Score

25.4

P/E

-7.5

P/B

3.48

ROE

-46.7%

Op. Margin

-290.6%

Debt Ratio

75%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -7.5x, P/B 3.48x. Ranks in the top 71% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -46.7%. Ranks in the top 90% of the universe.

Safety ★★★☆☆

Good

Debt ratio 75%. Ranks in the top 31% of the universe.

Growth ★★☆☆☆

Average

Revenue growth of 4.5% year over year. Ranks in the top 51% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	-1286.8	-1687
2019	$0.0B	$-0.1B	$-0.0B	$-0.1B	-656.8	-55
2020	$0.0B	$-0.1B	$-0.0B	$-0.1B	-656.8	-54
2021	$0.0B	$-0.1B	$-0.1B	$0.2B	-591.4	115
2022	$0.1B	$-0.1B	$-0.1B	$0.2B	-159.0	871
2023	$0.4B	$0.1B	$0.1B	$0.5B	14.1	168
2024	$0.1B	$-0.3B	$-0.3B	$0.8B	-250.0	30
2025	$0.1B	$-0.3B	$-0.3B	$0.7B	-290.6	75